Rice A, Troendle E, Bridgett S, Firoozi Nejad B, McKinley J, Bradley D
Genome Med. 2024; 16(1):150.
PMID: 39702217
PMC: 11658175.
DOI: 10.1186/s13073-024-01409-1.
Lo E, Fortin E, Gilca R, Trepanier P, Geagea H, Zhou Z
Can Commun Dis Rep. 2024; 50(1-2):63-76.
PMID: 38655241
PMC: 11037885.
DOI: 10.14745/ccdr.v50i12a08.
Sultana N, Nagesha S, Lakshminarayana Reddy C, Ramesh B, Shyamalamma S, Shashidhara K
Virol J. 2024; 21(1):88.
PMID: 38641844
PMC: 11031966.
DOI: 10.1186/s12985-024-02365-3.
Goller K, Ziemann J, Kohler C, Becker K, Hubner N, The CoMV-Gen Study Group
Viruses. 2024; 16(3).
PMID: 38543819
PMC: 10974208.
DOI: 10.3390/v16030454.
Ghildiyal T, Rai N, Rawat J, Singh M, Anand J, Pant G
J Immunol Res. 2024; 2024:9125398.
PMID: 38304142
PMC: 10834093.
DOI: 10.1155/2024/9125398.
Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.
Huang P, Chang H, Zhang R, Wu Y, Qi P, Peng Y
Ann Hematol. 2023; 103(3):729-736.
PMID: 38151521
DOI: 10.1007/s00277-023-05593-9.
High Transmission Rates of Early Omicron Subvariant BA.2 in Bangkok, Thailand.
Petcharat S, Supataragul A, Hirunpatrawong P, Torvorapanit P, Klungthong C, Chinnawirotpisan P
Adv Virol. 2023; 2023:4940767.
PMID: 38094619
PMC: 10719011.
DOI: 10.1155/2023/4940767.
Assessing the importance of demographic risk factors across two waves of SARS-CoV-2 using fine-scale case data.
Wood A, Sanchez A, Bessell P, Wightman R, Kao R
PLoS Comput Biol. 2023; 19(11):e1011611.
PMID: 38011282
PMC: 10703279.
DOI: 10.1371/journal.pcbi.1011611.
Medium-term scenarios of COVID-19 as a function of immune uncertainties and chronic disease.
Saad-Roy C, Morris S, Baker R, Farrar J, Graham A, Levin S
J R Soc Interface. 2023; 20(205):20230247.
PMID: 37643641
PMC: 10465195.
DOI: 10.1098/rsif.2023.0247.
The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2.
Fang L, Xu J, Zhao Y, Fan J, Shen J, Liu W
Front Microbiol. 2023; 14:1228128.
PMID: 37560529
PMC: 10409611.
DOI: 10.3389/fmicb.2023.1228128.
Mutational Analysis of Circulating Omicron SARS-CoV-2 Lineages in the Al-Baha Region of Saudi Arabia.
Almalki S, Izhari M, Alyahyawi H, Alatawi S, Klufah F, Ahmed W
J Multidiscip Healthc. 2023; 16:2117-2136.
PMID: 37529147
PMC: 10389082.
DOI: 10.2147/JMDH.S419859.
The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice.
Miteva D, Kitanova M, Batselova H, Lazova S, Chervenkov L, Peshevska-Sekulovska M
Vaccines (Basel). 2023; 11(7).
PMID: 37514997
PMC: 10385722.
DOI: 10.3390/vaccines11071181.
Creating a Vaccine-like Supplement against Respiratory Infection Using Recombinant Spores Expressing SARS-CoV-2 Spike Protein with Natural Products.
Chan B, Li P, Tsang M, Sung J, Kwong K, Zheng T
Molecules. 2023; 28(13).
PMID: 37446658
PMC: 10343243.
DOI: 10.3390/molecules28134996.
Genomic surveillance of severe acute respiratory syndrome coronavirus 2 in Burundi, from May 2021 to January 2022.
Nduwimana C, Nzoyikorera N, Ndihokubwayo A, Ihorimbere T, Nibogora C, Ndoreraho A
BMC Genomics. 2023; 24(1):312.
PMID: 37301830
PMC: 10257533.
DOI: 10.1186/s12864-023-09420-3.
SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis.
Nguyen N, Nguyen Y, Hoang V, Million M, Gautret P
Viruses. 2023; 15(4).
PMID: 37112949
PMC: 10145185.
DOI: 10.3390/v15040967.
Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants: A population-based, matched cohort study.
PLoS One. 2023; 18(4):e0282806.
PMID: 37104488
PMC: 10138229.
DOI: 10.1371/journal.pone.0282806.
Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 and Variants Using Digital Droplet Polymerase Chain Reaction at a Large University and Healthcare System in California.
Stafylis C, Pernet O, Hernandez-Tamayo C, Kovacs A, Emerson J, Ward P
Open Forum Infect Dis. 2023; 10(4):ofad147.
PMID: 37089777
PMC: 10117372.
DOI: 10.1093/ofid/ofad147.
Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study.
Zheng Q, Bao C, Ji Y, Li P, Ma Z, Wang X
Sci Rep. 2023; 13(1):5474.
PMID: 37016035
PMC: 10071263.
DOI: 10.1038/s41598-023-32619-z.
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.
Tseng H, Ackerson B, Bruxvoort K, Sy L, Tubert J, Lee G
Nat Commun. 2023; 14(1):189.
PMID: 36635284
PMC: 9836332.
DOI: 10.1038/s41467-023-35815-7.
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.
Al-Hatamleh M, Abusalah M, Hatmal M, Alshaer W, Ahmad S, Mohd-Zahid M
J Taibah Univ Med Sci. 2022; 18(3):600-638.
PMID: 36570799
PMC: 9758618.
DOI: 10.1016/j.jtumed.2022.11.007.